/Investor DB

3E Bioventures Capital — 2021 Investments

2 investments dated 2021 · listed companies and verified rows first · show all

Alebundalebund.cominSep 2021 · $54.5M

An innovative biopharmaceutical company focused on developing therapies for chronic kidney disease across multiple clinical stages, with a pipeline of eight products covering conditions such as hyperphosphatemia, renal anemia, IgA nephropathy, and diabetic kidney disease.

BiotechDigital HealthHealthtechMedical DevicesShanghai, CN

Co-investorsLAVLilly Asia VenturesQuan Capital3H Health InvestmentSherpa Healthcare PartnersYuanBio Venture Capital

Cullgencullgen.comin𝕏Series B · Feb 2021 · $50M

Cullgen is a privately held biopharmaceutical company developing first-in-class drugs based on its uSMITE™ (small-molecule induced ubiquitin-dependent target elimination) targeted protein degradation platform, which uses the ubiquitin-proteasome system and E3 ubiquitin ligases to target disease-causing proteins that conventional small-molecule drugs cannot reach.

BiotechDeep TechHealthtechMedical Devices

Ying Luo(CEO)in

Co-investorsHongShan Capital Group

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.